Background The relevance of blood lipid concentrations to long-term incidence of cardiovascular disease and the relevance of lipid-lowering therapy for cardiovascular disease outcomes is unclear. We investigated the cardiovascular disease risk associated with the full spectrum of bloodstream non-HDL cholesterol concentrations. We also created an easy-to-use tool to estimate the long-term probabilities for a cardiovascular disease event associated with non-HDL cholesterol and modelled its risk reduction by lipid-lowering treatment.
Introduction
Numerous studies have provided consistent evidence for a causal relationship between blood cholesterol concen trations and cardiovascular disease. 1, 2 Calculating the concentration of nonHDL cholesterol offers a simple way to analyse the total amount of proatherogenic lipoproteins containing apolipoprotein B (apoB). 3 Such proteins include very lowdensity lipoproteins and their metabolic remnants, intermediatedensity lipoproteins, lipoprotein(a), and lowdensity lipoproteins. 3 Besides estimating cholesterol concentrations contained in LDL particles (LDL cholesterol), the assessment of nonHDL cholesterol calculated as total cholesterol minus HDL cholesterol is therefore recommended by current US and European guidelines for cardiovascular risk estimation. 4, 5 The indication for lipidlowering therapy to prevent car diovascular disease events in highrisk individuals or for secondary prevention is unequivocal. [4] [5] [6] [7] [8] [9] However, the decision on implementing a lipidlowering intervention in the primary prevention setting is a major challenge in clinical practice for several reasons. Data on the association between the concentrations of the entire range of bloodstream lipids and very longterm cardio vascular outcomes in the general population are rather sparse. 10, 11 In addition, conventional primary prevention guidelines recommend lipidlowering inter vention on the basis of lipid concentration thresholds and the person's individual 10year cardiovascular risk. 4, 5 This risk assessment might underestimate or fail to take proper account of the cumulative lifetime risk of cardiovascular disease and lipidrelated cardiovascular disease risk, par ticularly in young adults. 12 Furthermore, increased nonHDL cholesterol blood concentrations early in life seem to be stable over the life course and are predictive for incident cardiovascular disease. 13 Therefore, in this study we aimed to (1) evaluate longterm risk for cardiovascular disease in the population related to nonHDL cholesterol on the basis of existing thresholds of blood lipid concentrations; (2) establish an easily applicable tool to assess the longterm probabilities for cardiovas cular disease events associated with nonHDL choles terol, using a derivation and validation approach; and (3) provide a model indicating the potential benefit of an early lipidlowering strategy in individuals without prevalent cardiovascular disease.
Methods

Study design and participants
In this riskevaluation and riskmodelling study, we used individuallevel data from the Multinational Cardiovascular Risk Consortium (appendix pp [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . Currently, the Consortium comprises data on 524 444 individuals from 44 populationbased co horts across Europe, Australia, and the USA. These include 23 harmonised cohorts from the MONICA Risk Genetics Archiving and Monograph (MORGAM) 14 and Biomarker for Cardiovascular Risk Assessment in Europe (BiomarCaRE) 15 studies and another 21 harmo nised, populationbased cohorts with the same
Research in context
Evidence before this study The blood concentrations of non-HDL and LDL cholesterol are accepted as causal cardiovascular risk factors and constitute a cornerstone of cardiovascular disease risk prediction in the general population. The benefit of lipid-lowering interventions for cardiovascular disease risk reduction is proven by mendelian randomisation studies, prospective epidemiological cohort studies, and randomised trials. For the present study, we assessed recommendations made by the European and US guidelines and their underlying references for lipid-lowering strategies in primary prevention. Furthermore, we reviewed the cardiovascular risk calculators as recommended by these guidelines (Systematic COronary Risk Evaluation [SCORE] and Pooled Cohort Equations). We found very little data describing the effect of baseline non-HDL and LDL cholesterol on long-term or even lifetime outcomes. Cardiovascular risk assessment was mainly based on 10-year medium-term follow-up. All identified randomised trials for lipidlowering intervention in cardiovascular primary prevention did not exceed a follow-up of 7 years and, moreover, especially young individuals were underrepresented in those studies.
Added value of this study
To our knowledge, our study provides the most comprehensive analysis of long-term risk for cardiovascular disease related to non-HDL cholesterol and offers an easily applicable tool to assess the long-term probabilities for cardiovascular disease events associated with non-HDL cholesterol. On the basis of a derivation and validation approach to risk prediction, our data provide robust multinational information. By using an up-to-date multinational population-based pooled cohort dataset, we provide a model that calculates the potential benefit of an early lipid-lowering strategy in individuals without prevalent cardiovascular disease across a range of non-HDL cholesterol categories.
Implications of all the available evidence
There is evidence for the positive outcomes in lipid-lowering interventions in individuals with cardiovascular disease or those with very high cholesterol concentrations. Our data extend current knowledge and highlight the impact of non-HDL cholesterol on very long-term cardiovascular disease outcomes. A simulation of early reduction of non-HDL cholesterol across a range of lipid concentration categories estimates the risk reduction in the general population. Meeting targets for global reduction of cardiovascular disease morbidity and mortality will require increased awareness of the value of early cholesterol determination and careful evaluation of potential strategies for reduction of lipid concentrations across the lifespan. specifi cations as defined for the BiomarCaRE and MORGAM projects (appendix pp [15] [16] [17] [18] . Of these, we used cohorts that had available data on cardiovascular disease end points (appendix pp [16] [17] [18] . We excluded data on participants with prevalent cardiovascular disease, defined as a history of myocardial infarction, coronary artery bypass grafting, percuta neous transluminal coronary angioplasty, or ischaemic or haemorrhagic stroke. Detailed information about the study cohorts including the number of individuals with available information for each variable are provided in the appendix (pp [19] [20] [21] [22] [23] [24] [25] [26] [27] . Informed consent was obtained if necessary (depending on survey year and local requirement). Detailed information for each cohort is given in the study descriptions (appendix pp 2-11).
Procedures
Our outcome measure was the first occurrence of a major cardiovascular event (appendix pp [16] [17] [18] . This was assessed in all participating individuals and death of non cardiovasculardisease cause was used as a competing risk if appropriate. We defined it as a composite endpoint of the first nonfatal or fatal coronary heart disease or ischaemic stroke event. Coronary heart disease was defined as a composite of nonfatal or fatal myocardial infarction including unstable angina, coronary death, and coronary revascularisation. Outcomes were measured in each prospective cohort study by standardised followup (visit, report, registry information, etc; details are given for each cohort, appendix pp 2-11). Composite endpoint information for current analyses is provided in the appendix (pp [16] [17] [18] . There were no secondary outcomes.
We based our cholesterol threshold concentrations on the treatmentdetermining cholesterol categories of the 2016 European guidelines on cardiovascular disease prevention. 16 As recommended by the guidelines, we calculated nonHDL cholesterol thresholds by adding 30 mg/dL to the LDL cholesterol thresholds defined in our cohorts. Our analyses were based on baseline information avail able for concentrations of nonHDL cholesterol and LDL cholesterol. We report threshold concentrations in mmol/L, assuming that 1 mmol/L contains 38·67 mg/dL of LDL cholesterol and nonHDL cholesterol (for nonHDL cholesterol, the following categories were used: <100 mg/dL [<2·6 mmol/L]; 100 to <145 mg/dL [2·6 to <3·7 mmol/L]; 145 to <185 mg/dL [3·7 to <4·8 mmol/L]; 185 to <220 mg/dL [4·8 to <5·7 mmol/L], and ≥220 mg/dL [≥5·7 mmol/L]). The cutoff between the second and third category differs slightly from the European guidelines. We adapted this cutoff from 130 mg/dL (3·4 mmol/L) to 145 mg/dL (3·7 mmol/L), since the latter is the goal for lipid lowering therapy recommended for individuals at low risk, 4 who comprise most of our study population.
The following study variables were considered for analysis (but were not endpoints): age, sex, year of examination, bodymass index (BMI), systolic blood pressure, smoking status, use of cholesterollowering medication, total cholesterol, HDL cholesterol, and nonHDL cholesterol. History of arterial hyperten sion, diabetes, stroke, and myocardial infarction were defined as they had been documented or selfreported. Anti hypertensive medication, lipidlowering medication, and smoking status were selfreported. For individuals receiving lipidlowering therapy, baseline concentrations of nonHDL cholesterol and LDL cho lesterol were inflated by 30% for the analyses, assuming that treatment with statins had a moderate effect on lipid reduction and was initiated late during lifetime. 17 Information about individuals receiving lipidlowering therapy stratified by survey decades and age is shown in the appendix (p 28).
Statistical analysis
For each analysis, only individuals with all data available on the relevant variables were used. To investigate the association of nonHDL cholesterol concentrations and time to cardiovascular disease, sexspecific cumulative incidence curves were produced according to the defined baseline nonHDL cholesterol threshold concentra tions, with death of noncardiovasculardisease causes as competing risk, using the AalenJohansen estimator. Multivariable Cox proportional hazards models were then computed, stratified for cohort and sex. NonHDL cholesterol was coded as a categorical variable, with the help of dummy variables, using our predefined thresholds and included an interaction term with sex, to obtain sexspecific associations. To examine the association of nonHDL cholesterol across different ages, the models were expanded by adding an interac tion between age category (<45, 45-59, and ≥60 years at baseline) and nonHDL cholesterol. Additional Cox regression analyses were done to model the concen trations of nonHDL cholesterol as a continuous variable via cubic splines. All Cox models were adjusted for age (timescale), sex (strata), cohort (strata), and classical cardiovascular risk factors (smoking status, diabetes, BMI, systolic blood pressure, and anti hypertensive medication). In a sensitivity analysis, sexspecific hazard ratios (HRs) for nonHDL cholesterol as a categorical variable were estimated in each country using models similar to the primary analysis, and the results were pooled using a randomeffects multivariate metaanalysis. Further sensitivity analyses include the computation of timedependent HRs for nonHDL cholesterol to examine deviations from the proportional hazards assumption (appendix p 29).
To establish a tool to assess the probability of car diovascular disease by the age of 75 years, we split the whole data randomly into two parts of approximately equal size into derivation and validation datasets. In particular, each single cohort was part of both datasets. Using those observations where the required endpoint and covariate information was available, we developed a model that was calculated on the basis of cause specific Cox models for cardiovascular disease stratified for sex and cohort. Death from noncardiovascular disease causes was added as a competing risk, to account for the fact that an individual dying from such a cause before developing cardiovas cular disease will not be able to develop cardio vascular disease. These models used age as the timescale and the same variables as our previous Cox models. NonHDL cholesterol, BMI, and systolic blood pressure were modelled using cubic splines. The models included an interaction between nonHDL cholesterol and sex. The model computation used the full available followup periods but was applied only to individuals aged between 35 and 70 years at baseline to estimate their probability of cardiovascular disease by the age of 75 years. These predicted probabilities were averaged within each combination of sex, nonHDL cholesterol category, age category, and according to whether the number of risk factors present (smoking, arterial hypertension, diabetes, and obesity) was greater than or equal to two, or less than two. We then assumed a reduction of the probabilities and their averages through a 50% or 30% reduction of nonHDL cholesterol, on the basis of the equation 1 -exp(-0·249 + [number of years of treatment-5] × [-0·0152]) for the expected proportional risk reduction per mmol/L in LDL cholesterol for a given treatment duration. 2 It was assumed that this equation was also valid for nonHDL cholesterol. Fol lowing the methods described by Austin, 18 these average probabilities can then be used to estimate risk differences, numbers needed to treat, and differences in relative risk.
To obtain predicted probabilities from the cause specific Cox models for each combination of sex and cohort, the respective causespecific baseline hazard function was estimated by fitting a Weibull curve to age and adjusting for the linear predictor of the Cox model. By using age as the timescale, it is possible to estimate the probability of an event within each combination of sex and cohort for the whole range of ages available in that part of the data. Cindices and smooth calibration curves were calculated for different timeframes separately in the derivation and validation datasets. The calibration curves were based on smoothing pseudo values calculated with the AalenJohansen estimate of cumulative incidence. 19 Tenfold crossvalidation was used in these computations.
Sensitivity analyses used timedependent coefficients that were allowed to change with attained age in the predefined groups (<45, 45-59, and ≥60 years). To calculate the effect of nonHDL cholesterol reduction on cardiovascular risk, we assumed a reduction of baseline nonHDL cholesterol by 30% or 50% (adapted from the 2018 American College of Cardiology/American Heart Association Guideline on the Management of Blood Cholesterol). 5 On the basis of this reduction, we recalculated the probability of a cardiovascular disease event by the age of 75 years, as in our predictive model. The models and their averaged predictions were calcu lated in the derivation cohorts and also independently in the validation cohorts, and the discrepancy between the average predictions was compared using the root mean square error. This last step was repeated using the complete dataset, excluding each country in turn and also in the excluded country, thus generating country specific root mean square errors. The final models and their predictions were computed in the complete dataset. Cumulative inci dence curves for specific combinations of variables were produced on the basis of the causespecific Cox models. Here, we also assumed a 50% reduction in nonHDL cholesterol for the included individuals. Applying this equation for the expected proportional risk reduction for a given treatment duration could yield a nonmonotonic curve. Therefore, the resulting curves were forced to remain constant in the event of a decrease.
To compare the discrimination of a model using non HDL cholesterol with that of a model using LDL cholesterol, additional causespecific Cox models were computed using age as the timescale, sex and cohort as strata, adjusting for cardiovascular risk factors (smoking status, diabetes, BMI, systolic blood pressure, and antihypertensive medication), and including a sex-lipid variable interaction. All continuous variables, except age, were modelled using cubic splines. Tenfold crossvali dation was used when computing the Cindices. The main analyses for nonHDL cholesterol were repeated for LDL cholesterol. All statistical methods were implemented in R statistical software, version 3.6.1.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author (SB) and the lead statistician (FO) had full access to all the data in the study, and the corresponding author had final responsibility for the decision to submit for publication.
Results
We identified 38 co horts reporting on 398 846 individuals with 5 604 735 personyears of followup data available for analysis, of whom 184 055 (48·7%) were women (tables 1 and 2, appendix pp [19] [20] [21] [22] [23] [24] [25] [26] [27] 30) . Examination years ranged from 1970 to 2013 (years for each cohort are given in the appendix pp [19] [20] [21] [22] [23] [24] [25] [26] [27] figure 3 ). This association remained consistent in a sensitivity analysis using a randomeffects multivariate metaanalysis (appendix p 31). The steepest increase of the relative hazard associated with nonHDL cholesterol was found in individuals younger than 45 years at 
Figure 3: Age-specific and sex-specific association of non-HDL cholesterol and cardiovascular disease
Lifetime sex-specific HRs for fatal and non-fatal cardiovascular disease (reference non-HDL cholesterol <2·6 mmol/L) in the overall cohort and according to three age categories (p<0·001 for the interaction of age and non-HDL cholesterol categories in women and in men). The Cox regression models were adjusted for age at baseline, sex, study cohort, smoking, diabetes, body-mass index, systolic blood pressure, and antihypertensive medication. HR=hazard ratio. baseline (maximum HR 4·3, 95% CI 3·0-6·1 in women and 4·6, 3·3-6·5 in men, for nonHDL cholesterol ≥5·7 mmol/L). Within the older groups, the association of nonHDL cholesterol with incident cardio vascular disease was attenuated but still detectable in individuals aged 60 years and older (HR 1·4, 95% CI 1·1-1·7 in women and 1·8, 1·5-2·2 in men, for nonHDL cholesterol ≥5·7 mmol/L; p<0·001 for the inter action of age and nonHDL cholesterol categories in women and in men; figure 3 ). Similar results were found in sensitivity analyses excluding individuals with diabetes (appendix p 38) and those receiving lipidlowering therapy (appendix p 39) at baseline. The associ ation of nonHDL cholesterol and cardiovascular disease remained consistent after addi tionally adjusting for HDL cholesterol (appendix p 40). We found similar results for the association of blood concentrations of LDL cholesterol and incident cardio vascular disease to nonHDL cholesterol (appendix p 32). Cardiovascular disease event rates increased stepwise with increasing LDL cholesterol categories (appendix p 41). Multivariable analyses showed a linear association of LDL cholesterol with cardiovascular disease on the loghazard scale, with the lowest relative risk for cardio vascular disease in the individuals with the lowest LDL cholesterol concentrations (appendix p 42). The strongest association was detected in individuals younger than 45 years and was attenuated in individuals aged 60 years and older (p<0·001 for the interaction of age and LDL cholesterol category in women and in men; appendix p 43).
To estimate the longterm probability of a car diovascular disease event associated with nonHDL cholesterol, we established a model for cardiovascular disease risk up to the age of 75 years on the basis of a derivation-vali dation approach. Besides the nonHDL cholesterol category, sex, age, and the baseline number (≤1 vs ≥2) of classical modifiable cardiovascular risk factors (ie, arterial hypertension, dia betes, obesity, and smoking) were incorporated into this model ( figure 4) . For example, women with nonHDL cholesterol concen trations between 3·7 and 4·8 mmol/L, younger than 45 years, and with at least two additional cardiovascular risk factors had a 15·6% (95% CI 14·9-16·6) probability of experiencing a nonfatal or fatal cardiovascular disease event by the age of 75 years (28·8%, 28·1-29·5 in men with the same character istics). The highest longterm risk of cardiovascular disease was seen in individuals younger than 45 years of age. The risk predictions obtained from this model were highly comparable in the derivation and validation datasets with a root mean square error lower than 1% for the estimated probabil ities of cardiovascular disease (appendix p 44). Country specific root mean square errors, as well as Cindices and smooth calibration curves specific for sex and followup time are provided in the appendix (pp 33, 34, 45). Further sensitivity analyses using timedependent HRs did not show relevant differences in the prediction of cardiovascular disease by the age of 75 years (appendix p 46).
We calculated the optimally achievable risk reduction for cardiovascular disease by the age of 75 years assuming a 50% reduction of nonHDL cholesterol ( figure 4 ). In the population with nonHDL cholesterol of 3·7-4·8 mmol/L, younger than 45 years, and with at least two risk factors, the longterm risk of cardiovascular disease could hypo thetically be reduced from 15·6% (95% CI 14·9-16·6) to 3·6% (3·4-3·8) in women and from 28·8% (28·1-29·5) to 6·4% (6·3-6·6) in men. Further, corresponding numbers of patients needed to treat over the lifespan up to the age of 75 years, and achievable relative risk reduction (RRR) are shown in table 3. For example, in the same individuals, the number needed to treat to reduce one cardiovascular disease event over the lifespan by the age of 75 years was 8·3 in women and 4·5 in men, with RRR of 77% in women and 78% in men (see appendix p 35 for estimates with a 30% reduction of nonHDL cholesterol). Additionally, we computed the incidence for cardiovascular disease and the achievable risk reduction due to 50% reduction of nonHDL cholesterol for specific individuals starting at different ages. Absolute risk reductions of cardiovascular disease were more pronounced in individuals with two or more cardiovascular disease risk factors than in those with one or no risk factors, and in men than women. Within each category, the greatest effect was found for the youngest individuals (appendix pp 36, 47).
Discussion
Using individuallevel data from the Multinational Cardiovascular Risk Consortium of individuals without prevalent cardiovascular disease, we characterised the agespecific and sexspecific longterm association of non HDL cholesterol with cardiovascular disease. On the basis of this association, we derived and validated a tool specific for age, sex, and cardiovascular risk factors to assess the individual longterm probability of cardio vascular disease by the age of 75 years associated with nonHDL cho lesterol. Further, we modelled the poten tially achievable longterm cardiovascular disease risk, assuming a 50% reduction of nonHDL cholesterol. The proatherogenic effects of apoBcontaining lipopro teins are largely based on the development and progression of atherosclerotic plaques and by accumulation of these lipoproteins within the arterial intima. 20, 21 Although the measurement of LDL cholesterol can be influenced by increased triglycerides 22, 23 in cardiovascular risk asses sment, an appropriate way to estimate the amount of apoBcontaining lipoproteins is the determination of non HDL cholesterol. 3, 21, 24, 25 Therefore, our main analyses are based on nonHDL cholesterol. In line with previous studies, we found a comparable prognostic relevance for nonHDL cholesterol and LDL cholesterol. 26 A large body of evidence including inherited disorders, 27 genetic 28, 29 and epidemiological studies, 10, 11 and clinical trials 7-9 leads to the hypothesis that reducing apoBcontaining lipo proteins, regardless of the method, should yield a corresponding reduction in cardiovascular events. To intervene early and intensively during the lifespan might even lead to regression of early manifestation of atherosclerosis. 30 Epidemiological studies have shown the association between cholesterol concentration and cardiovascular mortality during longterm followup. 11, 31 Furthermore, repeated nonHDL cholesterol testing in 2516 individuals of the Framingham Offspring Study suggested that stable concentrations over the lifetime 13 might represent increased risk of cardiovascular disease. Clinical trials, however, mostly address older (age >60 years for most studies) individuals with prevalent cardiovascular disease or at markedly increased cardio vascular risk and report obser vations over short followup intervals, varying between 2 and 7 years. [7] [8] [9] Considerable uncertainty exists about the extent to which slightly increased or apparently normal cholesterol concentrations affect lifetime cardiovascular risk and about which thresholds should be used to merit a treat ment recommendation, particularly in young people. Our study extends current knowledge because it suggests that increasing concentrations of nonHDL cholesterol predict longterm cardiovascular risk, particularly in cases of modest increase at a young age. Only a few studies have reported the agedependent association of lipids and cardiovascular disease with focus on young individuals. 10, 11, 13 In our analyses, individuals younger than 45 years showed the strongest HRs for the association of blood lipids with the incidence of cardiovas cular disease during longterm followup. This effect is probably related to the following considerations: (1) the effect of lifetime accumulation of proatherogenic lipids in the vulnerable period of the fourth and fifth decades of life, 32 (2) the shorter timespan that individuals aged 60 years and older have to achieve the cardiovascular disease endpoint due to their age itself, and (3) the fact that people with prevalent cardiovascular disease are not included in our study and thus individuals who reach the age of 60 without prevalent cardiovascular disease are a population enriched with protective charac teristics against the proatherogenic effect of cholesterol. However, although there is a weaker association of nonHDL cholesterol with cardiovascular disease in older indi viduals (>60 years), these people are at higher absolute risk than young individuals, and so the more modest relative risks represent large absolute risk differences across nonHDL cholesterol categories. 10 The risk circle tool displays the individual lifetime risk of nonfatal and fatal cardiovascular disease by the age of 75 years that is associated with nonHDL cholesterol and is specific for the burden of age, sex, and risk factor. It also estimates the corresponding risk reduction from lipidlowering therapies. The risk scores currently used for decision making about lipidlowering intervention assess only the 10year cardiovascular risk 33, 34 and there fore underestimate lifetime risk, particularly in young individuals. 11, 12 Pencina and colleagues 31 esti mated the 30year risk of cardiovascular disease in the Framingham Offspring cohort and showed 30year risks that were up to ten times higher than the projected 10year risks in young people. 31 Therefore, in young individuals, the longterm risk of cardiovascular disease should constitute the basis of primary prevention. Since the risk factor burden is incorporated as a categorical variable in our model, we cannot provide a weighting among the different risk factors or a quantitative con sideration of every single risk factor as do other risk models. Instead, because of its simplicity, our risk circle tool provides an opportunity to estimate lifetime risks based on non HDL cholesterol in an accessible and easily understood way that can improve physician-patient communication about preventive strat egies in clinical practice. The modelled risk reduction is calculated hypothetically and is based on a 50% lipid reduction leading to a decrease of the cumulative burden of nonHDL cholesterol. Since the calculated numbers needed to treat are based on different timeframes for different age ranges, they have to be compared carefully between the different age categories. They have to be interpreted individually for a certain spectrum of ages, sexes, and risk factors to guide decision making on any lipidlowering inter vention. Furthermore, numbers needed to treat might be higher than those we showed in lowrisk countries with lower than average cardiovascular disease incidence and mortality.
The following limitations merit consideration. First, due to the populationbased longitudinal study design, the endpoint information is mainly based on medical reports or local registers and we cannot exclude misclassification of endpoints for some of the observed effects. However, endpoint information was harmo nised on the basis of individual data according to the specification of the MORGAM study, and multivariable analyses were adjusted for potential confounders. Therefore, the best achievable data quality can be assumed for the current analyses. Second, only baseline data of blood lipids were available for current analyses. No information about dynamic changes during follow up or about the initiation of lipidlowering therapy, particularly in those individuals with very high blood concentrations, could be considered. 35 However, non HDL cholesterol concentrations in young individuals are generally stable over the 30year life course, 13 and not adjusting for changes in risk factors was shown to have little bearing on lifetime cardiovascular disease risk. 31 Third, our cohorts largely included individuals with European ancestry from highincome countries in Europe, North America, and Australia. The general isability of our findings to other regions or individuals from other racial and ethnic groups is unknown. Finally, the therapeutic benefit of lipidlowering intervention investigated in our study is based on a hypothetical model that assumes a stable reduction of nonHDL cholesterol. We recognise that making such an assump tion posits that treatment effects are sustained over a much longer term than has been studied in clinical trials and that realworld benefits of taking statins are probably lower than those shown in trials because of adherence and sideeffects. 36 However, since clinical trials investigating the benefit of lipidlowering therapy in individuals younger than 45 years during a follow up of 30 years are not available, our study provides unique insights into the benefits of a potential early intervention in primary prevention. We agree with HippisleyCox and colleagues 37 that future research needs to address many related questions, including whether intervention in young people with a high lifetime risk but low 10year risk would yield greater benefits than late intervention.
